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What, exactly, is ‘gene therapy’? Commissioner Scott Gottlieb of the U.S. Food and
Drug Administration’s (‘FDA’s’) recently announced his agency’s intent to develop an
expedited approval pathway for ‘gene therapy’ despite the lack of any precise definition
by regulators or scientists.1,2 At least 25 new therapeutic products have billed them-
selves as ‘gene therapies’, including several treatments—notably, adenovirus associated
vectors (‘AAV’) and ex vivoT-cell therapies—that raise difficult questions as to the con-
tours of the term.3,4,5 As of this writing, there are more than 700 active investigational
1 Alex Phillipidis, 25 Up and Coming Gene Therapies, May 7, 2018, https://www.genengnews.com/the-lists/
25-up-and-coming-gene-therapies/77901090 [archived at http://perma.cc/8KNE-3M9J].
2 FDA, Remarks by Commissioner Gottlieb to the Alliance for Regenerative Medicine’s Annual Board Meeting,
May 22, 2018, https://www.fda.gov/NewsEvents/Speeches/ucm608445.htm [archived at http://perma.cc/
D9VN-VXSQ].
3 FDA,Luxturna, Jan. 17, 2018, https://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/
ApprovedProducts/ucm589507.htm [archived at https://perma.cc/YA9H-QYM3].
4 FDA, Yescarta (axicabtagene ciloleucel), Nov. 16, 2017, https://www.fda.gov/BiologicsBloodVaccines/
CellularGeneTherapyProducts/ApprovedProducts/ucm581222.htm [archived at https://perma.cc/
4QDY-W2AX].
5 FDA,Kymriah (tisagenlecleucel), Sept. 27, 2017, https://www.fda.gov/BiologicsBloodVaccines/CellularGene
TherapyProducts/ApprovedProducts/ucm573706.htm [archived at https://perma.cc/4EM4-9GQX].
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new drug applications for ‘gene therapies’.6 And yet, FDA’s definition of ‘gene therapy’
dates back to 1993—ancient history relative to recent advances in the field.7,8
This debate concerning what constitutes ‘gene therapy’ is important beyond mere
semantics.Crystallizing amoderndefinitionof ‘gene therapy’ hasnowbecomecritically
important on several fronts. Following the recent of passage the 21st Century Cures
Act, FDAnow relies on the term to give regulatory incentives to sponsors of certain ‘re-
generative medicines’, including ‘gene therapies’.9,10 NIH Director Francis S. Collins
and FDA Commissioner Scott Gottlieb recently announced that Recombinant DNA
Advisory Committee (‘RAC’) approval would no longer be required for ‘gene therapy’
because ‘there is no longer sufficient evidence to claim that the risks of gene therapy are
entirely unique and unpredictable’.6 And in July 2018 FDA issued six draft guidance
documents on ‘gene therapy’, but none with a substantially new definition.11 The term
also carries significant baggage regarding drug pricing, with ‘gene therapies’ seeming
to command higher premiums relative to other advanced biotherapeutics. And the ad-
vent of gene-edited ex vivo therapies, such as CAR-T, has further complicated the use
of the phrase. Ultimately, the difference between calling a therapy a ‘gene therapy’ and
something else is thedifferencebetween a slate of regulatory incentives, streamlined ap-
proval, specificmanufacturing guidances, and, likely, premiumprices and public cache.
Today’s core difficulty in defining ‘gene therapy’ lies in categorizing genetic modi-
fications that do not directly modify a pathogenic gene in vivo. Autologous cell treat-
ments, for example, do genetically modify patients’ own cells, but outside of the
body—ex vivo.2,4 That, under some definitions, is ‘gene therapy’. But such therapies
impart new genes into cells rather than fix a specific genetic failure. This is not ‘gene
therapy’, in the skeptic’s view, because the therapy itself has nothing to do with defi-
ciencies in a patient’s genetic makeup.
Properly defining gene therapy is ultimately important for understanding and com-
municating the state of the science, and for helping regulators tailor and clarify both
incentives and requirements for those products appropriately characterized as ‘gene
therapy’.This is so even as our understanding of what constitutes a ‘gene’ continues to
change. We review the contours of the term here, and propose that ‘gene therapy’—in
the lay, scientific, and legal sense—should be defined as an intentional and expected
permanent alteration of a specific DNA sequence of the cellular genome—that is, the
sum of DNA that exists within a cell—for a clinical purpose. We also propose that
gene therapy, as we define it, can be further categorized into at least three types: direct,
6 Francis S. Collins&ScottGottlieb,TheNext Phase ofHumanGene-TherapyOversight, NEWENGL. J.MED. (Aug.
15 2018).
7 FDA,What is GeneTherapy?, Jan. 9, 2018, https://www.fda.gov/BiologicsBloodVaccines/CellularGeneTher-
apyProducts/ucm573960.htm [archived at https://perma.cc/WY6A-CNTM].
8 FDA, Application of current statutory authorities to human somatic cell therapy products and gene therapy
products. 58 Fed. Reg. 53248–53251 (Oct. 14, 1993).
9 21st Century Cures Act, 144 Pub. L. 255, 130 Stat. 1033 (2016).
10 FDA,DraftGuidance, Expedited Programs for RegenerativeMedicineTherapies for SeriousConditions,Nov.
2017,https://www.fda.gov/downloads/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/
guidances/cellularandgenetherapy/ucm585414.pdf [archived at https://perma.cc/EZ23-QR8G].
11 Zachary Brennan, FDA Unveils 6 New Draft Guidances on Gene Therapy. REGULATORY FOCUS, July 11, 2018,
https://www.raps.org/news-and-articles/news-articles/2018/7/fda-unveils-6-new-draft-guidances-on-gene-
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compensatory, and augmenting. Defining gene therapy in this fashion would provide
clarity to scientists and regulators alike.
PRIOR ATTEMPTS TO DEFINE ‘GENE THERAPY ’
SinceWatson andCrick’s discovery of themolecular structure ofDNA, the ‘HolyGrail’
of molecular biology has been the ability to precisely edit the genome of in living tis-
sue.12 The functional idea behind this aspiration is that by replacing some of a body’s
genetic material, researchers and clinicians can effectively reprogram genetic illnesses.
But underlying this goal lies a deep-philosophical line-drawing problem: all therapies,
in some sense, affect a patient’s genes, whether it’s through altering transcription, reg-
ulating translation, or even modifying the epigenome. A relaxing vacation—sun, surf,
and sangria—arguably does more to regulate gene expression than many ‘precision’
therapies.
Beginning in the 1970s, scientists attempted to cabin gene therapy with a concrete,
practical definition. In a 1972 article in Science, Ted Friedmann and Richard Roblin
first proposed that a definition of ‘gene therapy’ required ‘exogenous “good” DNA be
used to replace the defective DNA in those who suffer from genetic defects’.13 But, as
Friedmann andRoblin noted, the time’s ‘understanding of such basic processes as gene
regulation and genetic recombination in human cells [was] inadequate’ to make trials
ethical.11 This did not, however, prevent some unauthorized trials in humans shortly
thereafter.14 By 1986, molecular biology had progressed enough to convene a meeting
of the Institute ofMedicine (IOM) to propose the first likely ‘gene therapy’ candidates,
with a focus on ‘gene therapy’ as the addition or replacement of a gene in a targeted,
somatic cell type.12
In the same year, FDA finalized its position that it has jurisdiction over—andwould
subject to regulatory approval—human gene therapy, albeit without clearly defining
the term. Stakeholders’ requests for more guidance from the agency, as well as con-
tinued advances in the science, eventually led FDA, in 1993, to define ‘gene therapy’
in an official Notice that aimed to clarify the FDA’s overall regulatory approach. Gene
therapies are those used to ‘modify or manipulate the expression of genetic material or
to alter the biological properties of living cells’5—a definition broad enough to cover
any treatment and seemingly intended to ensure FDA retained oversight over a then
fast-moving technology. FDA recently reiterated this definition in draft guidance issued
in July 2018, adding that gene therapies are those ‘products that mediate their effects
by transcription or translation of transferred genetic material or by specifically altering
host (human) genetic sequences’.15 In its 1993 Notice, FDA also distinguished ‘gene
therapy’ from ‘somatic cell therapy’—cells ‘propagated, expanded, selected, pharma-
cologically treated, or otherwise altered’ for therapeutic purposes—a definition signifi-
cantly overlapping with that of ‘gene therapy’.7 Others suggested abandoning the term
12 Giedrius Gasiunas & Virginijus Siksnys, RNA-Dependent DNA Endonuclease Cas9 of the CRISPR System: Holy
Grail of Genome Editing? 21 TRENDSMICROBIOL. 562–67 (2013).
13 Theodore Friedmann & Richard Roblin, Gene Therapy for Human Genetic Disease? 175 SCIENCE 949–55
(1972).
14 Mule J. Cline,GeneTherapy: Current Status, 83 AM. J. MED. 291–97 (1987).
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‘gene therapy’ altogether in favor of ‘gene transfer’ to avoid implying that the unproven
interventions provided clinical benefit.
Attempts to define ‘gene therapy’ waned after the 1999 death of Jesse Gelsinger,
a clinical trial subject who succumbed to complications arising from the viral vector
used to repair a congenital enzymatic deficiency.16 After his death, the term ‘gene ther-
apy’ took on a more negative connotation as a dangerous and unproven technology.13
But the advent of newer genetic engineering technologies—such as CAR-T and
CRISPR—has refreshed perceptions over gene therapy’s possibilities. CRISPR, espe-
cially, has ignited the public imagination over a safe, easy, and practicable form of gene
therapy.17
DEFINING ‘GENE THERAPY ’ TODAY
Prior definitions of gene therapy are problematic for several reasons. First, several
definitions—such as Friedmann&Roblin’s and the IOM’s 1986 definition—required
the replacementof somaticDNAwithexogenousDNA.Modernbiotechnologies, how-
ever, can alter a cell’s genomewithout either replacing ormodifying somaticDNA. Sta-
bly transfected AAV therapy, such as Luxturna (voretigene neparvovec-rzyl), adds to
the cellular genome without modifying any endogenous sequences.2 And some varia-
tions of CRISPR can edit somatic DNAwithout the need for exogenous genetic mate-
rial.18 Second, other definitions of gene therapy—such as FDA’s—are so broad as to
be essentially meaningless. FDA’s definition of ‘gene therapy’ requires merely a modi-
fication of genetic expression—a feature of almost all small molecule drugs, as well as
food, drink, sleep, andmuch else. Further, ‘gene transfer’ is too narrow of a term—one
may alter the human genome without transferring a gene to the target, such as through
single-base, or evenmultiple-base gene-editing, as is frequently the case usingCRISPR.
Given these recent advances, we propose defining human ‘gene therapy’ as the in-
tentional, expected permanent, and specific alteration of the DNA sequence of the cel-
lular genome, for a clinical purpose. Our definition requires only that the modification
is expected to persist in the cell during its life, not that it is irreversible. Genetic modi-
fications lost over time, such as the loss of transfected episomes, would not be perma-
nent.19 Further, our definition is agnostic as to whether such modification takes place
inside patient’s body or, as with CAR-T, outside of it. It is also agnostic as to vector.
Indeed, for these reasons, we think our definition encompasses the historical thrust of
gene therapy toward novel delivery approaches, including recent and potentially future
developments in biotechnology. It is also flexible: While our definition centers on so-
matic gene therapy, it would equally apply to germline therapy—should it ever come to
fruition—as well. Our definition would also include therapies that for reasons typically
having todowithdosing,would requiremultiple deliveries—so long, of course, as a sin-
gle course of treatment is expected to be permanent. Finally, we believe that because
16 Jennifer Couzin & Jocelyn Kaiser, As Gelsinger Case Ends, Gene Therapy Suffers Another Blow, 307 SCIENCE
1028b (2005).
17 Thomas Gaj, Charles A. Gersbach & Carlos F. Barbas, III, ZFN, TALEN, and CRISPR/Cas-Based Methods for
Genome Engineering, 31 TRENDS BIOTECH. 397–405 (2013).
18 Nicole M. Gaudelli et al., Programmable Base Editing of A T to G C in Genomic DNAWithout DNA Cleavage,
551 NATURE 464–71 (2017).
19 Anja Ehrhardt, Hui Xu &Mark A. Kay, Episomal Persistence of Recombinant Adenoviral Vector Genomes During
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Table 1. Subsidiary categories of gene therapy.
Type of Gene
Therapy Definition Example
Direct The intentional modification of
a specific somatic gene in order
to correct defective genes or to
fix an allele’s malign function.
Single-base pair editing to
resolve insertions or deletions
that lead to defective proteins.
Compensatory The induction of expression of
genetic material that
compensates for lost or
aberrant cellular function.
Editing of gene to increase or
decrease expression in target
cell, or induce expression
normally turned off.
Augmenting The introduction of a novel
function that would not
otherwise be present in the
target cell type.
Editing of a gene to provide a
different function from what is
typical; insertion of a new
version of a gene into the
genome (as opposed to editing
the existing version)
our definition requires the intent to alter a specific gene, it best resolves many of the
philosophical issues inherent in distinguishing true gene therapy from other therapies
that have an incidental effect on gene expression without altering genetic sequences.
Our definition of gene therapy is susceptible to further characterization. We pro-
pose that gene therapy, as we define it, can be grouped into at least three subsidiary
categories: direct, compensatory, or augmenting (Table 1). Direct gene therapy con-
stitutes the intentionalmodificationof a specific somatic gene to correct defective genes
or to fix an allele’s malign function, such as the modification of defective blood factor
genes associated with hemophilia, or the repair of CFTR gene as a cure for cystic fi-
brosis. Compensatory gene therapy, by contrast, induces the expression of related ge-
neticmaterial that compensates for some lost or aberrant cellular function.One current
attempt is the inducement—and permanent expression of—fetal hemoglobin to cure
sickle cell anemia and β-thalassemia.20,21 Lastly, augmenting gene therapy introduces,
again through the stable transfection of genetic material, a novel function that would
not otherwise be present in the target cell type. This includes several anti-cancer treat-
ments that insert geneticmaterial encoding synthetic immunoreceptors as amethod to
augment immune function against tumors.22
We offer a few observations in support of our definition’s value. First, it resolves the
status of three recently approved therapies that once strained the definition of ‘gene
therapy’, Luxturna,Kymriah (tisagenlecleucel), andYescarta (axicabtagene ciloleucel).
All concern some expected permanent change to a cell’s genome, whether ex vivo or
20 Chiara Antoniani et al., Induction of Fetal Hemoglobin Synthesis by Crispr/Cas9-Mediated Disruption of the β-
globin Locus Architecture, 128 BLOOD 321 (2016).
21 Alessia Finotti et al., Recent Trends in the GeneTherapy of β-thalassemia, 6 J. BLOODMED. 69–85 (2015).
22 Francisco J. Sánchez-Rivera & Tyler E. Jacks, Applications of the CRISPR–Cas9 System in Cancer Biology, 15
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in situ. Changes to genetic coding or expression that, for whatever reason, will revert
back to their prior state in the absence of continued therapy are unlikely to be con-
sidered ‘gene therapy’; they are not permanent and in that sense are no different from
therapies or other stimuli that merely have an incidental effect on gene expression.
Second, despite our labeling of these treatments as ‘gene therapy’, none fit within the
classical—and, we think, outdated—definition of gene therapy as the direct alteration
of a ‘defective’ nuclear gene.To that end,webelieve our definition better aligns the con-
cept of ‘gene therapy’ to currently used technologies.Third, therapies that permanently
alter DNA sequences within the cellular genome, but do so in a haphazard or unknown
fashion—as with some carcinogens—should not be considered gene therapy; they fail
our intent requirement. Lastly, all three examples concern modifications to a patient’s
cells.Modification of cells that originally did not derive from the same patient—even if
those cells are human cells—should, too, not be construed as ‘gene therapy’ any more
than organ transplantation, which transplants the donor’s genome, or the geneticmod-
ification of a patient’s microbiota, should be.These, instead, would be forms of ‘tissue’
or ‘cell therapy’.
We believe our definition of ‘gene therapy’ is a significant improvement over prior
attempts. FDA’s current definition, for example,would includenonpermanent oligonu-
cleotide therapy—like RNAi therapies—that are decidedly not ‘gene therapy’.23 Our
definition encompasses but moves beyond older conceptions of gene therapy that re-
quire the direct editing of a pathogenic variant of particular gene. That definition, by
contrast, has proven too narrow.The somatic editing of a benign transcription factor or
the insertion of an exogenous gene to improve the functioning of a different genewould
fail to be considered gene therapy under these older definitions. Again, we think these
criticisms of current definitions of gene therapy illuminate the fundamental character-
istics of true ‘gene therapy’ in both the scientific and legal sense: the permanent mod-
ification or addition of the DNA sequence within a patient’s own cells. Furthermore,
our characterizations of gene therapy into discrete types—direct, compensatory, and
augmenting—would allow regulators to particularize the different safety and efficacy
concerns involving each type. For example, labeling a gene therapy as either direct or
compensatory—where little recombinant DNA is involved—may very well give cre-
dence to FDA’s and NIH’s recently announced intention to forgo RAC review.6 But
recognizing a gene therapy as augmenting—where novel genetic material imparts a
new function to patients’ cells—may call for ‘using theRAC as an advisory board on
today’s emerging biotechnologies’.6
Under our definition, we also think it is important to clarify what our definition of
gene therapy does not do. Our definition is not specific to either vector or mechanism.
Regarding vector, genetic modification effected by virii, lipid nanoparticles, or cells
should all still be considered genetic therapy. We see no reason why one vector should
fall within the confines of gene therapy but another should not; the genetic and func-
tional modification of the genome remains the same. Similarly, we see no reason why
one mechanism of editing—assuming its permanency—should constitute gene ther-
apy over any other.The darling of current gene-editing efforts, CRISPR, could be used
in our definition of gene therapy equally well as others, such as TALENs, zinc-finger
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nucleases, and simple homologous repair mechanisms. For our definition’s purposes,
gene therapy can be effected using any vector.
Finally, our definition provides room for further change and growth within
its scope. Today, we can categorize gene therapies as direct, compensatory, and
augmenting—but there are likely more ways of altering the cellular genome than
dreamt of in our philosophies. Should another therapeutic approach emerge that
changes the DNA sequence of the cellular genome, we would not object to forming
new categories of gene therapy so long as it is intentional, expected to be permanent,
and specific.
CONTEMPORARY APPLICATION: CAR-T
With our definition of gene therapy in hand, we can more closely examine one philo-
sophically difficult therapy—CAR-T—as an example of how our definition can work
robustly in application.OneCAR-T therapy,Kymriah, for example, works by removing
some of a patient’s white blood cells; editing the cells to recognize and target leukemic
B-cells; and reinserting the edited cells back into the patient in the hopes of using the
modified cells’ T-cell receptors and thebody’s own immune system todestroy leukemic
cells. In particular, the patient’s cells are modified to express a recombinant targeting
molecule—aT cell, with a synthetic chimeric antigen receptor.4 Thatmodification—a
type of augmenting gene therapy in our classification—makes Kymriah the first in a
class of novel therapies known as ‘CAR-T’. UponKymriah’s approval, there was heated
debate among the press and public about whether CAR-T was, in fact, ‘gene therapy’,
‘cell therapy’, or both,24 an important distinction for both regulators and insurers.
So, is CAR-T ‘gene therapy’? On balance, we think ‘yes’. CAR-T permanently mod-
ifies a patient’s own cells ex situ and returns those cells to the patient. The modifica-
tion is directed to a specific fragment of genes associated with T-cell receptor protein
chains—an expected permanent alteration for the life of those cells. And the specific
modification made—the precise sequence of the transfected genetic material—is in-
tentional.These facets would appear to make CAR-T ‘gene therapy’.The initial extrac-
tion of cells from the patient is unimportant; our definition would be the same if the
same result were achieved in vivo through the use of a viral vector. In both cases, a spe-
cific gene in a patient’s own cells has been intentionally and permanently modified.
Nonetheless, we should note that we do not disagree with Kymriah’s simultaneous
characterization as ‘cell therapy’.The term ‘cell therapy’—both in FDA’s definition and
elsewhere—refers to the therapy’s vector, ie cells, as opposed to the therapy’s function.
Again, our definition of ‘gene therapy’ is agnostic as to vector. In such instances, some
therapiesmay verywell be both cell therapy and gene therapy.This is, we believe, nodif-
ferent from referring to a therapy—such as Luxturna—as both viral therapy and gene
therapy. Indeed, this is precisely the type of gene therapy originally contemplated by
the IOM in 1986: ex situ ablative bone marrow gene therapy using viral vectors.12 Our
definition is robust in that it both encompasses easy cases fromdecades ago and current
therapies today.
24 Melissa Healy, Hailing a Breakthrough in Fighting Cancer, FDA Approves Gene Therapy that Functions
as a ‘Living Drug’, LOS ANGELES TIMES, Aug. 30, 2017, http://www.latimes.com/science/sciencenow/






/jlb/article/5/3/786/5078563 by Illinois U
niversity user on 06 August 2021
Is it ‘gene therapy’?  793
CONCLUSIONS
Crafting a modern definition of ‘gene therapy’ is not merely an exercise in
semantics—it’s important for regulators, scientists, and the public. A workable defini-
tion serves as a goodmarker for whether we have successfully found a broad version of
molecular biology’s ‘HolyGrail’. Until we can stably, permanently, and intentionally al-
ter any genes of our choosing in living patients, we think it fair to say that we have yet to
succeed in that goal. Better defining gene therapy also provides more regulatory clarity
than currently exists. Understanding that determining whether something constitutes
‘gene therapy’ is independent of vector suggests that the overall safety and efficacy of
the editing process, rather than the nature of the vector, should be the primary focus of
regulation. That is, our definition of gene therapy makes clear that the safety and effi-
cacy of gene therapy means the safety and efficacy of the edits themselves are of a dif-
ferent nature than narrower issues for the vector chosen.We also hope that crystalizing
a definition of gene therapy would improve the public’s understanding of an otherwise
scientifically difficult term. On a broader level, concretely defining gene therapy allows
us to benchmark progress in clinicalmolecular biology as advances pass through proofs
of concept and ultimately regulatory review. At the very least, we expect our definition
to be a focus for discussion about what ‘gene therapy’ means and why definitions are
important.
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